Futura Medical plc interim results for the six months ended 30 June 2014
11 September 2014 | By Futura Medical plc
Futura Medical plc is pleased to announce its interim results for the six months ended 30 June 2014...
List view / Grid view
News
European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe
10 September 2014 | By Boehringer Ingelheim
The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above...
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa
10 September 2014 | By GlaxoSmithKline
GSK announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases in Africa, as part of GSK’s Africa NCD Open Lab initiative...
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression
10 September 2014 | By Novartis
Novartis announced that new data presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, reinforces the clinical importance of measuring brain shrinkage (brain volume loss) in multiple sclerosis...
FDA Advisory Committee recommends against approval of Actavis’ Nebivolol/Valsartan fixed-dose combination NDA for treatment of hypertension
10 September 2014 | By Actavis
Actavis plc confirmed that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension...
DPT Laboratories acquires Meda Pharmaceuticals’ Lakewood, New Jersey, Location
10 September 2014 | By DPT Laboratories
DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities...
Mundipharma announces results of pivotal phase III study for flutiform® in paediatric asthma
8 September 2014 | By Mundipharma
New data from a randomised, multicentre, phase III study, being presented at the European Respiratory Society (ERS) annual congress in Munich, Germany, supports the potential of flutiform® for the treatment of paediatric asthma...
Roche’s RoACTEMRA receives EU approval for use in patients with early rheumatoid arthritis (RA)
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
8 September 2014 | By AstraZeneca
Results are among key AstraZeneca respiratory data being presented at 2014 European Respiratory Society International Congress...
Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care
8 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU...
New Abbott technology may uncover the root of critical infections and cut health care costs
8 September 2014 | By Abbott
A new study suggests a pioneering testing technology could reduce hospital stays by up to eight days and lower annual health care costs for people with serious infections by approximately $2.2 million (€1.5 million / £1.2 million)...
GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions
8 September 2014 | By GlaxoSmithKline
GSK presented data at the European Respiratory Society Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid containing regimen...
Merck receives accelerated approval of KEYTRUDA® (pembrolizumab), the first FDA-approved anti-PD-1 therapy
5 September 2014 | By Merck
Merck announced that the U.S. Food and Drug Administration has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimuma...
Teva announces launch of generic Baraclude® Tablets, 0.5mg and 1mg, in the United States
5 September 2014 | By Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States...
Abbott receives CE Mark for FreeStyle® Libre, a revolutionary glucose monitoring system for people with diabetes
5 September 2014 | By Abbott
Abbott announced that it has received CE Mark for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes...
